Gut Permeability and Microbiota in Parkinson’s Disease: Mechanistic Insights and Experimental Therapeutic Strategies
International Journal of Molecular Sciences · 01.10.2025 · 26 (19) · 9593
DOI: 10.3390/ijms26199593 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.10.2025. Verfasst von Yicheng Liang und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Biological Science, University of California-Davis, One Shields Avenue, Davis, CA 95616, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Gastrointestinal Microbiome. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Globally, Parkinson’s disease (PD) is the neurodegenerative condition with the most rapidly increasing prevalence, and a growing body of evidence associates its pathology with impairments in the gut–brain axis. Traditionally viewed as a disease marked by the loss of dopaminergic neurons, emerging evidence emphasizes that chronic neuroinflammation is a driver of neurodegeneration, with gut-originating inflammation playing a crucial role. Increased intestinal permeability, often called “leaky gut,” allows harmful substances, toxins, and misfolded α-synuclein into the systemic circulation, potentially exacerbating neuroinflammation and spreading α-synuclein pathology to the brain through the vagus nerve or compromised blood–brain barrier (BBB). This review synthesizes current insights into the relationship between gut health and PD, emphasizing the importance of gut permeability in disrupting intestinal barrier function. This paper highlights innovative therapeutic approaches, particularly personalized therapies involving gut microbiome engineering, as promising strategies for restoring gut integrity and improving neurological outcomes. Modulating specific gut bacteria to enhance the synthesis of certain metabolites, notably short-chain fatty acids (SCFAs), represents a promising strategy for reducing inflammatory responses and decelerating neurodegeneration in Parkinson’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Biological Science, University of California-Davis, One Shields Avenue, Davis, CA 95616, USA.
- Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
ORCID-Profile: Alessio Fasano
Förderung
- NIDDK NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Liang, Y., Zhao, Y., Fasano, A., & Su, C. W. (2025). Gut Permeability and Microbiota in Parkinson’s Disease: Mechanistic Insights and Experimental Therapeutic Strategies. International Journal of Molecular Sciences, 26(19), 9593. https://doi.org/10.3390/ijms26199593
Vancouver
Liang Y, Zhao Y, Fasano A, Su CW. Gut Permeability and Microbiota in Parkinson’s Disease: Mechanistic Insights and Experimental Therapeutic Strategies. International Journal of Molecular Sciences. 2025;26(19):9593. doi:10.3390/ijms26199593
BibTeX
@article{Liang2025,
author = {Liang, Yicheng and Zhao, Yuhang and Fasano, Alessio and Su, Chien-Wen},
title = {Gut Permeability and Microbiota in Parkinson’s Disease: Mechanistic Insights and Experimental Therapeutic Strategies},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {19},
pages = {9593},
doi = {10.3390/ijms26199593}
}
EUVIMED